These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7448342)

  • 1. Pharmacokinetics of isosorbide dinitrate after intravenous infusion in human subjects.
    Taylor T; Chasseaud LF; Doyle E; Darragh A; O'Kelly DA; Fitzgerald D
    Biopharm Drug Dispos; 1980; 1(3):149-56. PubMed ID: 7448342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isosorbide 5-mononitrate pharmacokinetics in humans.
    Taylor T; Chasseaud LF; Major R; Doyle E; Darragh A
    Biopharm Drug Dispos; 1981; 2(3):255-63. PubMed ID: 7295882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isosorbide 5-mononitrate and isosorbide 2-mononitrate kinetics after intravenous and oral dosing.
    Straehl P; Galeazzi RL; Soliva M
    Clin Pharmacol Ther; 1984 Oct; 36(4):485-92. PubMed ID: 6478734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isosorbide 5-mononitrate kinetics.
    Major RM; Taylor T; Chasseaud LF; Darragh A; Lambe RF
    Clin Pharmacol Ther; 1984 May; 35(5):653-9. PubMed ID: 6713775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of isosorbide dinitrate and its mononitrate metabolites after intravenous infusion.
    Santoni Y; Iliadis A; Cano JP; Luccioni R; Frances Y
    J Pharmacokinet Biopharm; 1986 Feb; 14(1):1-17. PubMed ID: 3746630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetics of isosorbide dinitrate administered by intravenous infusion to hypertensive patients (author's transl)].
    Frydman A; Levenson J; Simon A; Safar M; Bieder A; Bertharion J; Gaillot J
    Nouv Presse Med; 1982 Jun; 11(27):2049-56. PubMed ID: 7110964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma concentrations of isosorbide dinitrate after cutaneous and sublingual doses to human subjects.
    Mansel-Jones D; Taylor T; Doyle E; Chasseaud LF; Darragh A; O'Kelly DA; Over H
    J Clin Pharmacol; 1978; 18(11-12):544-8. PubMed ID: 721951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and metabolism of isosorbide-dinitrate after intravenous and oral administration.
    Abshagen U; Betzien G; Endele R; Kaufmann B; Neugebauer G
    Eur J Clin Pharmacol; 1985; 27(6):637-44. PubMed ID: 3987768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability and metabolism of isosorbide dinitrate from a transdermal spray.
    Laufen H; Leitold M
    Arzneimittelforschung; 1992 Jul; 42(7):931-5. PubMed ID: 1418058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained-release formulations.
    Assinder DF; Chasseaud LF; Taylor T
    J Pharm Sci; 1977 Jun; 66(6):775-8. PubMed ID: 577507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma concentrations and bioavailability of isosorbide dinitrate and pindolol from a combination formulation.
    Chasseaud LF; Doyle E; Taylor T; Darragh A
    Biopharm Drug Dispos; 1981; 2(3):273-81. PubMed ID: 7295884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma concentrations of isosorbide dinitrate after oral administration of a sustained-release formulation to human subjects.
    Assinder DF; Chasseaud LF; Hunter JO; Jung RJ; Taylor T
    Arzneimittelforschung; 1977; 27(1):156-8. PubMed ID: 576817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newer aspects of the pharmacokinetics of organic nitrates.
    Chasseaud LF
    Z Kardiol; 1983; 72 Suppl 3():20-3. PubMed ID: 6666223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic extraction of isosorbide dinitrate in cardiac patients.
    Morrison RA; Wiegand UW; Jähnchen E; Höhmann D; Kasper W; Meinertz T; Fung HL
    Clin Pharmacol Ther; 1983 Dec; 34(6):724-31. PubMed ID: 6641086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isosorbide dinitrate plasma concentrations and bioavailability in human subjects after administration of standard oral and sublingual formulations.
    Chasseaud LF; Darragh A; Doyle E; Lambe RF; Taylor T
    J Pharm Sci; 1984 May; 73(5):699-701. PubMed ID: 6737249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isosorbide dinitrate kinetics and dynamics after intravenous, sublingual, and percutaneous dosing in angina.
    Morrison RA; Wiegand UW; Jähnchen E; Höhmann D; Bechtold H; Meinertz T; Fung HL
    Clin Pharmacol Ther; 1983 Jun; 33(6):747-56. PubMed ID: 6851405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of isosorbide dinitrate.
    Fung HL
    Am Heart J; 1985 Jul; 110(1 Pt 2):213-6. PubMed ID: 4013997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma concentrations of isosorbide dinitrate after administration of increasing doses of a sustained-release formulation to human subjects.
    Taylor T; O'Kelly DA; Major RM; Darragh A; Chasseaud LF
    Arzneimittelforschung; 1978; 28(8):1426-8. PubMed ID: 582411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of intravenous isosorbide-dinitrate.
    Platzer R; Reutemann G; Galeazzi RL
    J Pharmacokinet Biopharm; 1982 Dec; 10(6):575-86. PubMed ID: 7182455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man.
    Laufen H; Aumann M; Leitold M
    Arzneimittelforschung; 1983; 33(7):980-4. PubMed ID: 6684933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.